ENTERA BIO LTD. Selling, General and Administrative Expense
ENTERA BIO LTD. (ENTX) reported Selling, General and Administrative Expense of $124.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-07
- ENTERA BIO LTD. selling, general and administrative expense for the quarter ending 2026-06-30 was $124.00K, a 20.39% increase year-over-year.
- ENTERA BIO LTD. selling, general and administrative expense for the quarter ending 2026-03-31 was $128.00K, a 4.07% increase year-over-year.
- ENTERA BIO LTD. selling, general and administrative expense for the quarter ending 2025-12-31 was $54.00K, a 43.75% decline year-over-year.
- ENTERA BIO LTD. selling, general and administrative expense for the quarter ending 2025-09-30 was $122.00K, a 96.77% increase year-over-year.
- ENTERA BIO LTD. selling, general and administrative expense for fiscal 2025 was $398.00K, a 17.06% increase from fiscal 2024.
- ENTERA BIO LTD. selling, general and administrative expense for fiscal 2024 was $340.00K.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $124.00K 10-Q · filed 2026-08-07 | $252.00K 10-Q · filed 2026-08-07 | $306.00K derived: sum of 3 quarters · filed 2026-08-07 | $428.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $128.00K 10-Q · filed 2026-05-08 | $182.00K derived: sum of 2 quarters · filed 2026-05-08 | $304.00K derived: sum of 3 quarters · filed 2026-05-08 | $407.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $176.00K derived: sum of 2 quarters · filed 2026-03-27 | $279.00K derived: sum of 3 quarters · filed 2026-08-07 | $398.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | $122.00K 10-Q · filed 2025-11-14 | $225.00K derived: sum of 2 quarters · filed 2026-08-07 | $344.00K 10-Q · filed 2025-11-14 | $444.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $103.00K 10-Q · filed 2026-08-07 | $226.00K 10-Q · filed 2026-08-07 | $322.00K derived: sum of 3 quarters · filed 2026-08-07 | $384.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $123.00K 10-Q · filed 2026-05-08 | $219.00K derived: sum of 2 quarters · filed 2026-05-08 | $281.00K derived: sum of 3 quarters · filed 2026-05-08 | $415.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $158.00K derived: sum of 2 quarters · filed 2026-03-27 | $292.00K derived: sum of 3 quarters · filed 2026-03-27 | $340.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | $62.00K 10-Q · filed 2025-11-14 | $196.00K derived: sum of 2 quarters · filed 2025-11-14 | $244.00K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $134.00K 10-Q · filed 2025-08-08 | $214.00K 10-Q · filed 2025-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |